Thiazolidinedionerne virker primært ved at reducere insulinresistens og sulfonylurinstofferne virker primært ved at stimulere insulinfrigivelsen fra β- cellerne i pankreas.
Thiazolidinediones act primarily by reducing insulin resistance and sulphonylureas act primarily by stimulating release of insulin from functioning pancreatic β -cells.